TITLE

New dogmas or old?

AUTHOR(S)
Whittle B J R
PUB. DATE
September 2003
SOURCE
Gut;Sep2003, Vol. 52 Issue 9, p1379
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recent experimental studies may undermine our understanding of the gastrointestinal side effects of non-steroidal anti-inflammatory drugs and cast a shadow on the original concept that underpins the development of the recent addition to the clinical anti-inflammatory armamentarium, the COX-2 selective inhibitors. But is this just a passing cloud or a total eclipse of the COX theory?
ACCESSION #
10631328

 

Related Articles

  • Cyclooxygenase-2 Inhibition and Side-effects of Non-steroidal Anti-inflammatory Drugs in the Gastrointestinal Tract. Meyer-Kirchrath, J.; Schror, K. // Current Medicinal Chemistry;Nov2000, Vol. 7 Issue 11, p1121 

    Inhibition of prostaglandin biosynthesis via inhibition of the fatty acid cyclooxygenase (COX) is the mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). This results in an inhibition of the inflammatory and pain-producing activities of prostaglandins at a site of tissue...

  • NSAIDs: the Emperor's new dogma? Bjarnason I; Takeuchi K; Simpson R // Gut;Sep2003, Vol. 52 Issue 9, p1376 

    The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity...

  • Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003? Yuan, Yuhong; Hunt, Richard H. // Inflammopharmacology;2003, Vol. 11 Issue 4-6, p337 

    Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs worldwide despite their well-documented adverse gastrointestinal (GI) effects. The risk of developing a severe GI event varies from patient to patient and NSAID to NSAID. Selective cyclo-oxygenase-2 inhibitors...

  • Serious upper gastrointestinal complications of NSAIDs and COX-2 selective agents. Sisson, Guy; Bjarnason, Ingvar // Inflammopharmacology;Aug2011, Vol. 19 Issue 4, p183 

    The authors comment on studies that focus on the frequency and severity of the gastrointestinal side effects of non-steroidal anti-inflammatory drugs (NSAID) and cyclo-oxygenase-2 (COX-2) selective agents. They argue that in forming an opinion by researchers on the gastrointestinal safety...

  • COX-2 Inhibitors – Lessons in Drug Safety. Psaty, Bruce M.; Furberg, Curt D. // New England Journal of Medicine;3/17/2005, Vol. 352 Issue 11, p1133 

    The article focuses on the authors' views on the use of cyclooxygenase-2 (COX-2) inhibitors. The authors say that COX-2 inhibitors, which were meant to deflect the gastrointestinal complications common to other nonsteroidal anti-inflammatory drugs, have shown serious adverse cardiovascular...

  • What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;6/25/2002, Vol. 166 Issue 13, p1692 

    Discusses the use of non-steroidal anti-inflammatory agents (NSAID), which have been associated with gastrointestinal events. Safety concerns about selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex), which were developed as an alternative to NSAID;...

  • A COX-2-Specific Inhibitor Plus a Proton-Pump Inhibitor: Is This a Reasonable Approach to Reduction in NSAIDs' GI Toxicity? Cryer, Byron // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p711 

    The two prevailing approaches to decrease risks of nonsteroidal anti-inflammatory drug (NSAID)-associated gastrointestinal (GI) events are the use of a COX-2 inhibitor or co-therapy with a proton-pump inhibitor (PPI). A major limitation of each approach is that, in patients at the highest risk...

  • What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;6/25/2002, Vol. 166 Issue 13, p1692 

    Discusses the use of non-steroidal anti-inflammatory agents (NSAID), which have been associated with gastrointestinal events. Safety concerns about selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex), which were developed as an alternative to NSAID;...

  • Study evaluates aspirin comedication rates among long-term COX-2 inhibitor users.  // Formulary;Sep2004, Vol. 39 Issue 9, p434 

    Evaluates aspirin comedication rates among long-term COX-2 inhibitor users. Lack of difference in gastrointestinal infection ulcer complication rates between celecoxib and nonselective NSAID; Percentage of comedication with over-the-counter pain relievers.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics